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Shame and embarrassment related to Parkinson’s disease (PD) are rarely addressed in
clinical practice nor studied in neuroscience research, partly because no specific tool
exists to detect them in PD.
Objective: To develop a self-applied assessment tool of shame and embarrassment
specifically related to PD or its treatment, to promptly identify the presence and severity
of these two emotions in PD.
Methods: Identification and selection of relevant items were obtained from the collection
of PD patients’ opinions during support groups and interviews. Several further items were
added following a literature review. Subsequently, a two-phase pilot study was performed
for identification of ambiguous items and omissions, and to obtain preliminary data on
acceptability, reliability, validity and relevance of the new scale (SPARK).
Results: A total of 105 PD patients were enrolled in the study. Embarrassment was
reported in 85% of patients, while shame was present in 26%. Fifteen percent of
patients did not describe any shame or embarrassment. On average, the intensity of
these two emotions was low with a marked floor effect in SPARK items and subscales.
However, SPARK total score inter-individual variability was important (range 1–84 out of
99). Acceptability and quality of data were satisfactory with no floor or ceiling effects
(2.9% each) or missing data. Internal consistency (Cronbach’s alpha) was 0.94 for
total score and 0.73–0.87 for subscales. The scale correlated ≥0.60 with instruments
measuring related constructs. Content validity was satisfactory. SPARK total score
strongly correlated with impaired health-related quality of life (rS = 0.81), the propensity
to feel embarrassed or ashamed (rS = 0.68 and 0.66, respectively), and anxiety (rS =
0.72) and depression (rS = 0.63) levels. Moderate to high correlations were observed
between SPARK total score and apathy (rS = 0.46) and a more pronounced personality
trait directed toward harm avoidance (rS = 0.46). No significant differences in SPARK
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scores were found by sex, education level, PD duration, Hoehn and Yahr stages or
PD phenotype.
Conclusion: Preliminary analysis of psychometric properties suggests that SPARK
could be an acceptable and reliable instrument for assessing shame and embarrassment
in PD. SPARK could help healthcare professionals to identify and characterize
PD-induced shame and embarrassment.
Keywords: parkinson’s disease, shame, embarrassment, questionnaire, non-motor symptoms
INTRODUCTION
Patients affected with Parkinson’s disease (PD) perceive non-
motor symptoms as serious challenges and barriers to a satisfying
quality of life (1). PD-related shame and embarrassment are
rarely addressed in clinical practice nor studied in neuroscience
research (2). The prevalence of shame and embarrassment in PD
is unknown and no specific tool exists to detect and measure
them in PD.
Shame and embarrassment are two negative self-conscious
emotions associated with painful states, where the self (i.e., the
affective representation of one’s identity) is focal in attention.
The individual believes that she/he has failed to meet appropriate
standards of conduct, and thinks that she/he has done so in
the eyes of others. No consensus has been reached on how
shame and embarrassment differ (3). Intuitively, for English
speakers at least, shame and embarrassment are members of
the same family and the differences between the two are subtle.
The establishment of explicit differential criteria to distinguish
shame from embarrassment has proven difficult in the literature.
Shame is psychologically more challenging than embarrassment,
marked by intensely painful negative self-evaluation commonly
exhibited by an individual upon realizing that she/he has
committed an offense or violated an important (usually social)
norm. Shame is more long-lasting and produces more damage
to self-esteem. Shame is also associated with a more serious
breach of fundamental norms or rules. Upon contemplating
the transgression, the individual concludes that she/he is
incapable, worthless, fundamentally flawed, reprehensible, and
worthy of contempt. Whereas, embarrassment is about minor
transgressions or failures in role enactments or failure in one’s
ability to present her/himself to others in an ideal manner.
Embarrassment is associated with a motivational response
directed toward the preservation of one’s social reputation, rather
than a concern for others’ well-being and a need to make amends,
as in guilt, or with a concern for oneself with a need to hide as in
shame (4).
Abbreviations: BDI-II, Beck Depression Inventory II; LEDD, levodopa equivalent
daily dose; MDS-UPDRS motor score, motor scale of Movement Disorder
Society Unified Parkinson’s Disease Rating Scale; MOCA, MOntreal Cognitive
Assessment; PD, Parkinson’s disease; PD, phenotype: TR, tremor dominant,
AR, akinetorigid form; PDQ-8, Parkinson’s Disease Questionnaire 8 items
(Health-related quality of life); PFQ-2, Personal Feelings Questionnaire
(shame and embarrassment scale); SD, standard deviation; STAI, State-Trait
Anxiety Inventory; SPARK, Shame and embarrassment in PARKinson’s disease
questionnaire; TPQ, Tridimensional Personality Questionnaire.
Shame and embarrassment in PD may emerge from different
sources: (1) PD symptoms, especially visiblemotor symptoms but
also non-motor symptoms; (2) increasing physical dependence
and need for help induced by PD; and (3) deteriorated body
image (2). Consequences of PD-related shame on health-related
quality of life are probably important but have not been studied
in detail. Consequently, shame and embarrassment should be
actively explored and addressed in patients affected with PD.
To do so, a specific tool to detect and measure these
emotions in PD is needed. We therefore created a self-applied
questionnaire rating shame and embarrassment specifically
induced by PD or its treatment, to promptly identify the presence
and severity of these emotions in PD patients as well as to
better understand what clinically promotes these emotions. The
objective of this pilot study is to describe the development process
of this rating scale, including its conception and the analysis of its
relevance and adequateness to the target population as well as its
psychometric properties.
MATERIALS AND METHODS
The study was approved by the Geneva Ethics Committee. All
participants gave their informed written consent.
Identification and Selection of Items of
Interest (Phase 1)
Identification of relevant items was based on a set of opinions and
perspectives expressed by 44 PD patients during support groups
and informal interview. The inclusion criteria for participants
was a diagnosis of PD. The only exclusion criteria was the
presence of dementia. The content of the expressed views was
subsequently analyzed and reduced to a set of qualitative themes
or meaning units. This preliminary phase of the study was from
our point of view an essential component, as it allowed us
to better understand shame and embarrassment related to the
disease in PD patients. In addition, a comprehensive review of the
literature on shame and stigmatization in PD was carried out. It
revealed that the utterances expressed by patients were, generally,
on the mark. Following further understanding obtained from
this review process, new items were added to the emerging scale.
Extra items were implemented from two scales: 2 items from the
PDQ-39 (5) and 6 items from the Stigma Scale for Chronic Illness
8-item version (6). Data obtained during phase 1 provided the
construction of a preliminary scale including 26 items. Responses
reflected a scale of intensity (from 0 to 3: 0= not at all, 1= a little,
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2=moderately, 3= very much). The scale was called Shame and
embarrassment in Parkinson’s disease (SPARK).
Construction of the First Draft of the Scale
and Pre-testing (Phase 2)
The preliminary SPARK scale was applied to 26 patients with
a diagnosis of PD based on the United Kingdom Parkinson’s
Disease Society Brain Bank criteria (7). Patients were recruited
from the Neurology Department of the Geneva University
Hospital. PD patients with any kind of dementia (including
mild and moderate) defined by a Montreal cognitive assessment
(MOCA) score (8) <26/30 were excluded. A cognitive debriefing
questionnaire was administered after completion of the SPARK
scale, asking patients about their opinions on the relevance
of the subject for their medical follow-up, length of the
questionnaire, simplicity to respond, embarrassment with any
item, omissions and global view. This was done to identify
ambiguities, redundancies and omissions as well as to obtain
preliminary data of acceptability and relevance of the subject.
This questionnaire consists of 8 items with two possible answers
(yes or no). A space for text where subjects could express their
opinion was also available for each question.
Reformulation and Construction of the
Second Version of the Scale
The preliminary scale was adapted after the analysis of the
cognitive debriefing questionnaire. The new scale was reviewed
by five experts in PD and four experts in questionnaire validation.
A second version of the SPARK questionnaire was created, with
33 items grouped into 6 subscales: (1) Shame and embarrassment
arising from PD symptoms (items 1–5, 8, 11–16, 20); (2)
Shame and embarrassment arising from the increasing physical
dependence and need for help induced by PD (items 7, 10, 18);
(3) Shame and embarrassment arising from the deteriorated body
image (items 6, 9, 17, 19, 21); (4) Consequence of related shame
and embarrassment on patient’s self-esteem (items 22, 25, 26); (5)
Stigmatization (items 23, 24, 27–31); (6) Type of emotion (item
32 for embarrassment, item 33 for shame). A summary score was
calculated by adding up all individual item scores, for amaximum
of 99 points. The self-assessment SPARK questionnaire takes
∼5min to perform.
Testing of the Second Version of the Scale
(Phase 3)
Thirty-five PD patients with no dementia were enrolled. A
neurological assessment was performed including a brief medical
history aimed to determine PD duration, stage of the disease
established by Hoehn and Yahr scale (9), levodopa equivalent
daily dose (LEDD) (10) and educational level, as well as a
motor assessment including a MDS-UPDRS part 3 (11), the
determination of the type of PD phenotype (12) and the level
of dyskinesia using the Marconi Dyskinesia Rating Scale (13).
The previously described SPARK debriefing questionnaire used
during the pretesting phase was applied. Other questionnaires
were also administered to assess psychobehavioral symptoms
such as depression using the Beck Depression Inventory II (BDI-
II) (14), anxiety with the State-Trait Anxiety Inventory for Adults
(STAI) (15) and apathy with the Apathy scale (16). Personality
dimensions were assessed with the Tridimensional Personality
questionnaire (TPQ) (17). The impact on health-related quality
of life was studied with a shorter version of the Parkinson’s
Disease Questionnaire (PDQ)-39, called the PDQ-8 (18, 19).
To compare our results with two previously validated scales
exploring the propensity to feel embarrassed or ashamed, we used
the Personal Feelings Questionnaire (PFQ-2) (20–22) and the
Embarrassment scale (21, 23).
Construction of the Final Version of the
Scale
Patients’ comments provided during the debriefing questionnaire
were discussed between the authors. Comments judged relevant
were used to create the final version of the SPARK scale
(Figure 1 and Supplementary Data 1) that will be used in a
future validation study.
Data Analysis
Descriptive statistics of the sample characteristics and the applied
rating scales were carried out. SPARK psychometric properties
were studied only in the 35 PD patients who took part in phase
3 of the study. The following psychometric properties were
analyzed, following the Classical Test Theory (CTT) (24):
- Data quality and acceptability (25, 26): missing data (standard
criterion: <10%), fully computable data (criterion: >90%);
distribution of scores, floor and ceiling effects (criterion:
<15%) and skewness (criterion: between−1 and+1).
- Reliability in terms of internal consistency (27, 28): Cronbach’s
alpha (standard criterion: >0.70), inter-item correlation
(criterion: 0.20–0.75), item homogeneity coefficient (criterion:
>0.15) and corrected item-total correlation (criterion:≥0.30).
- Validity. Three aspects of validity were assessed: convergent
and known-groups validity (29), internal validity and content
validity. For convergent validity, Spearman rank correlation
(rS) was calculated between SPARK (total and subscale
scores) and scores obtained with the two previously validated
scales measuring shame and embarrassment as well as scores
obtained with scales measuring depression, anxiety, apathy,
type of personality and quality of life impact, constructs
that theoretically should be related with the shame and
embarrassment. A high correlation was established if the
coefficient value rS was ≥0.60 (30). A moderate to high
correlation was considered if rS was between 0.30 and 0.59.
A moderate or weak was defined if rS was <0.30. Known-
group validity was tested by determining the differences
in SPARK total and subscales scores with subgroups based
on sex, level of education according to the International
Standard Classification of Education, PD duration (by the
median), Hoehn and Yahr (9) severity stage, and type of
PD phenotype (using MDS-UPDRS scores and applying
the formula as explained in Supplementary Table) (12).
The Mann-Whitney test was utilized to determine the
significance of the differences. Internal validity was assessed by
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FIGURE 1 | The SPARK questionnaire.
means of the inter-correlation of domains, using Spearman’s
rank correlation coefficients (criterion, rS = 0.30–0.70). For
content validity, in addition to the input from experts
opinion and literature review during the construction process,
the qualitative evidence from the pre-testing debriefing
questionnaire with patients was analyzed, to ensure that
items in the scale were representative of the construct being
measured (28). For the debriefing questionnaire, the frequency
of yes/no responses was reported. The comments of the
patients were analyzed descriptively to assess their opinions.
All calculations were made using IBM SPSS version 25.0.
RESULTS
A total of 105 patients were enrolled in our study: 44 patients
for phase 1, 26 for phase 2 and 35 for phase 3 of the pilot study.
Demographic and clinical characteristics are reported in Table 1.
Among the 61 patients who participated in phases 2 and 3 of the
study, most patients (85%) were experiencing embarrassment,
whereas shame concerned fewer patients (26%). When shame
was present, embarrassment was always associated with it. Fifteen
percent of patients did not describe any shame or embarrassment.
The phase 3 of our study analyzed SPARK’s psychometric
properties. The SPARK total mean score was 23.97 (standard
deviation SD: 18.53; range: 1–84) (Table 2). SPARK total score
presented a skewness of 1.50, with no floor or ceiling effects (2.9%
each) or missing data. Responses to items covered the full range
of scale scores (0–3) except for 3 items. Most subscales and items
showed a marked floor effect (Table 2).
Regarding internal consistency (Table 3), Cronbach’s alpha
ranged from 0.73 (Physical dependence subscale) to 0.87
(subscale Self-esteem), with a value of 0.94 for the total score.
Item homogeneity coefficient ranged from 0.29 (PD symptoms
subscale) to 0.70 (Self-esteem subscale). Most items (except items
1, 3 and 24) showed an item-total corrected correlation >0.40.
SPARK total score strongly correlated with PDQ-8 (rS =
0.81), PFQ-2 total and Shame subscale (rS = 0.66 and 0.69,
respectively), Embarrassment scale (rS =0.68), STAI State and
Trait (rS = 0.62 and 0.72, respectively) and BDI-II (rS = 0.63)
(Table 4). Moderate to high correlations were observed between
SPARK total score and Apathy scale (rS = 0.46) and TPQ Harm
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TABLE 1 | Patients demographic and clinical characteristics for the three phases
of the study.
Numbers Median Range
(min-max)
Pilot study 1
Number of participants (men) 44 (15)
Age (years) 65 60–75
Disease duration in years 5.0 2–10
Pilot study 2
Number (men) 26 (16)
Age (years) 64.6 39–82
Hoehn and Yahr (/4) 2 1.5–4
Motor score MDS-UPDRS III (/132) 18 5–40
MOCA (/30) 28 26–30
Pilot study 3
Number (men) 35 (15)
Age (years) 67 43–77
Education level (I, II, ≥III) 4 I, 12
II, 19≥III
Disease duration in years 8.7 1.9–19.1
Motor score MDS-UPDRS III (/132) 17 6–54
Dyskinesia score (/28) 2 0–10
Levodopa-equivalent daily dose
(mg/day)
785 100–2,100
PD phenotype 10 TR,
24 AR,
1 Mixed
MOCA (/30) 29 26–30
Hoehn and Yahr (/4) 2 1.5–4
PDQ-8 (/32) 9 0–27
Apathy scale (Starkstein) (/42) 9 3–23
Anxiety state score (STAI) (/80) 25 20–58
Anxiety trait score (STAI) (/80) 34 23–58
Depression score (BDI-II) (/63) 9 1–28
BDI-II, Beck Depression Inventory II; Dyskinesia, Marconi Dyskinesia Rating scale; MDS-
UPDRS motor score, motor scale of Movement Disorder Society Unified Parkinson’s
Disease Rating Scale; MOCA, MOntreal Cognitive Assessment; PD, Parkinson’s disease;
PD, phenotype: TR, tremor-dominant; AR, akinetic-rigid dominant; PDQ-8, Parkinson’s
Disease Questionnaire; Education level, Level I is defined as subjects who received a
primary education, Level II a lower secondary education, and level 3 and above at least
an upper secondary education.
avoidance (rS = 0.46). A negative weak to moderate correlation
was observed between SPARK total score and age (rS = −0.37).
PD duration, LEDD, motor score and type of PD phenotype
showed weak to moderate correlations with SPARK. All SPARK
subscales significantly correlated with PDQ-8 (rS≥0.60). SPARK
subscales PD Symptoms and Body image strongly correlated (rS
= 0.68 and 0.73, respectively) with PFQ-2 Shame subscale; and
PD Symptoms and Stigma strongly correlated (rS = 0.63 and
0.68, respectively) with the Embarrassment scale. PD duration,
LEDD and MDS-UPDRS part 3 showed weak correlations
with SPARK.
Regarding known-groups validity (Supplementary Data 2),
SPARK total and subscales scores did not present significant
differences by sex, education level, PD duration, Hoehn and Yahr
severity stages or PD phenotype.
Regarding internal validity, SPARK subscales correlated from
0.31 to 0.74 between them (Table 5). In terms of content
validity, patients’ responses to the debriefing questionnaire
(Table 6) demonstrated that >85% of the group found the
scale to be relevant to their current situation, helpful for
their healthcare professionals to understand their current state,
understandable and with adequate length. Questions were
described as embarrassing or difficult to answer only by 8.6 and
11.4% of the sample, respectively. Thirty-two percent of patients
made comments. See Supplementary Data 3 for a summary of
patients’ comments. Some items were consequently modified
and some subitems were added in order to capture the topic as
comprehensively as possible. Comments on embarrassment and
shame induced by sleep disturbances such as daytime sleepiness
and acting out dreams were not included in the final version of
the scale because this comment was made by a single patient.
DISCUSSION
SPARK is a new self-administered questionnaire assessing shame
and embarrassment induced by PD. The aim of our study was
to show how SPARK was conceived and designed. In addition,
some psychometric properties have been tested to orient the
developers toward potential problems with the current structure.
Preliminary analyses of the psychometric properties suggest
that SPARK could be an acceptable and reliable instrument
for assessing shame and embarrassment in PD. Higher scores
of shame and embarrassment were related to impaired health-
related quality of life and higher levels of depression and anxiety.
Consequently, PD-related embarrassment and shame probably
deserve our attention. SPARK could be a useful tool for healthcare
professionals and researchers to identify and rate these two
negative emotions, as well as to better understand what clinically
promotes these two painful and disruptive emotions.
Regarding the psychometric analysis, SPARK had a
satisfactory acceptability and data quality with no missing
data, due to good procedures during data collection. Internal
consistency and internal validity were acceptable, suggesting that
the scores of our instrument were an adequate reflection of the
dimensionality of the construct (embarrassment and shame) that
we thought to measure. Content validity was very satisfactory,
with the vast majority of patients thinking that the questionnaire
was relevant to their current situation and could be helpful for
their healthcare professional for their follow-up. SPARK was
judged by patients as easily understandable and of adequate
length, taking about 5min to complete. The content validity was
excellent, probably due to the SPARK construction and testing
process which involved a collaborative effort with multiple
exchanges between PD patients and healthcare professionals
specialized in PD.
In terms of the frequency of shame and embarrassment
induced by PD, most of our patients (85%) were experiencing
embarrassment whereas shame concerned far fewer patients
(26%). When shame was present, it was associated with
embarrassment in 100% of cases. Our results argue for the
fact that embarrassment and shame are two closely related
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TABLE 2 | Data quality and acceptability of SPARK.
N Mean Median SD Skewness Min Max Floor effect % Ceiling effect %
Item SPARK1 35 0.89 1.00 0.90 0.49 0 3 42.90 2.90
Item SPARK2 35 1.26 1.00 0.98 0.44 0 3 22.90 14.30
Item SPARK3 35 0.46 0.00 0.74 1.76 0 3 65.70 2.90
Item SPARK4 35 1.09 1.00 1.07 0.59 0 3 37.10 14.30
Item SPARK5 35 0.86 0.00 1.11 0.97 0 3 54.30 14.30
Item SPARK 6 35 0.94 1.00 0.97 0.74 0 3 40.00 8.60
Item SPARK 7 35 0.60 0.00 0.81 1.23 0 3 57.10 2.90
Item SPARK 8 35 0.69 0.00 0.90 1.20 0 3 54.30 5.70
Item SPARK 9 35 0.74 0.00 1.12 1.21 0 3 62.90 14.30
Item SPARK 10 35 1.34 1.00 1.16 0.23 0 3 31.40 22.90
Item SPARK 11 35 0.86 0.00 1.11 0.97 0 3 54.30 14.30
Item SPARK 12 35 0.89 1.00 0.99 1.00 0 3 42.90 11.40
Item SPARK 13 35 0.77 1.00 0.91 1.23 0 3 45.70 8.60
Item SPARK 14 35 0.06 0.00 0.24 3.99 0 1 94.30 5.70
Item SPARK 15 35 0.46 0.00 0.92 1.82 0 3 77.10 5.70
Item SPARK 16 35 0.69 0.00 1.02 1.39 0 3 60.00 11.40
Item SPARK 17 35 0.60 0.00 0.91 1.65 0 3 60.00 8.60
Item SPARK 18 35 0.94 1.00 1.11 0.80 0 3 48.60 14.30
Item SPARK 19 35 0.86 1.00 0.97 1.11 0 3 42.90 11.40
Item SPARK 20 35 1.06 1.00 1.16 0.60 0 3 45.70 17.10
Item SPARK 21 35 0.77 0.00 0.97 0.90 0 3 54.30 5.70
Item SPARK 22 35 0.51 0.00 0.89 1.97 0 3 65.70 8.60
Item SPARK 23 35 0.40 0.00 0.60 1.26 0 2 65.70 5.70
Item SPARK 24 35 0.09 0.00 0.28 3.09 0 1 91.40 8.60
Item SPARK 25 35 0.34 0.00 0.84 2.44 0 3 82.90 5.70
Item SPARK 26 35 0.63 0.00 0.97 1.65 0 3 60.00 11.40
Item SPARK 27 35 1.00 1.00 1.16 0.71 0 3 48.60 17.10
Item SPARK 28 35 0.54 0.00 0.85 1.37 0 3 65.70 2.90
Item SPARK 29 35 0.29 0.00 0.67 2.75 0 3 80.00 2.90
Item SPARK 30 35 0.77 0.00 1.06 1.12 0 3 57.10 11.40
Item SPARK 31 35 0.71 0.00 1.07 1.22 0 3 62.90 11.40
Item SPARK 32
Embarrassment
35 1.34 1.00 0.87 0.37 0 3 14.30 11.40
Item SPARK 33 Shame 35 0.54 0.00 0.95 1.72 0 3 68.60 8.60
Subscale SPARK
PD symptoms
35 10.00 9.00 7.21 1.34 1 30 5.70 2.90
Subscale SPARK
Physical dependence
35 3.91 3.00 3.84 0.66 0 9 25.70 2.90
Subscale SPARK
Body image deterioration
35 2.89 3.00 2.52 1.32 0 15 17.10 2.90
Subscale SPARK
Self-esteem
35 1.49 1.00 2.42 2.17 0 9 48.60 5.70
Subscale SPARK
Stigmatization
35 3.80 3.00 3.94 0.96 0 15 28.60 2.90
SPARK Total (/99) 35 23.97 19.00 18.53 1.50 1 84 2.90 2.90
N, number of items in the questionnaire; SD, standard deviation.
self-conscious emotions belonging to the same continuum of
emotion, varying on a range of factors such as intensity,
public exposure and physical reaction (31). To the best
of our knowledge, the exact prevalence of the shame and
embarrassment in PD is unknown and our percentages would
have to be checked in a larger sample. Parkinson’s UK, a
patients’ association, found that 41% of PD patients reported
experiencing discrimination because of PD, including some
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experiences of misinterpretation of symptoms or verbal abuse in
public (32).
In terms of the intensity of shame and embarrassment, SPARK
total score had a mean of 24 out of 99 with a wide range
of scores (1–84) showing that the severity of the shame and
embarrassment varied greatly among patients. Floor effect in
SPARK items and subscales indicated that most patients showed
low levels of shame and embarrassment. However, SPARK scores
were associated with a lower level of health-related quality of life,
as well as with higher levels of depression and anxiety. Shame
and embarrassment may contribute to psychological difficulties
such as personal distress, self-identity alteration, social isolation,
TABLE 3 | Internal consistency of SPARK.
Subscales Item-total corrected
correlation
Cronbach’s
Alpha
Inter-item
correlation
Item
homogeneity
PD symptoms 0.01–0.71 0.84 −0.36–0.73 0.29
Physical
dependence
0.44–0.71 0.73 0.30–0.63 0.47
Body image 0.58–0.71 0.83 0.41–0.80 0.50
Self-esteem 0.71–0.85 0.87 0.59–0.77 0.70
Stigmatization 0.05–0.62 0.77 −0.13–0.70 0.32
depression, and social anxiety (33–36). The impact of shame and
embarrassment on patients’ quality of life might be exacerbated
by the fact that patients do not talk about this feeling because it
is a taboo subject (37). Many PD patients do not spontaneously
discuss these experiences with their relatives or their neurologist
because, ironically, they think that it is considered embarrassing
or shameful to talk about one’s embarrassment or the sources of
one’s shame (2).
The wide range of SPARK scores among patients probably
reflects the inter-individual variability of the experience of shame
and embarrassment. These two emotions vary depending on self-
awareness, personality traits, level of self-esteem and self-blame,
and culture (38–41). Our results are in accordance with this
assumption, whereby higher SPARK scores were related to the
personality propensity to feel embarrassed or ashamed and with
a personality trait directed toward harm avoidance.
The role of PD neuropathology itself in the experience
of shame and embarrassment is unknown. According to our
study, an indirect and a direct role of PD are probable.
An indirect role is probable through symptoms caused by
PD as well as the increasing physical dependence and the
deteriorated body image. However, a direct role of PD on the
emotional experience might also be associated, but remains
to be demonstrated. PD is secondary to neurodegeneration
involving predominantly dopaminergic neurons (42). Higher
TABLE 4 | Convergent validity of SPARK scale and subscales.
PD
Symptoms
Physical
dependence
Body image Self- esteem Stigma Item 32
Embarr.
Item 33
Shame
SPARK
TOTAL
Age −0.33 −0.27 −0.19 −0.23 −0.36* −0.34* −0.45** −0.37*
Duration of PD 0.20 −0.09 0.22 −0.03 0.03 −0.13 −0.33 0.10
LEDD 0.27 −0.03 0.18 0.00 0.08 −0.12 0.04 0.11
MOCA −0.23 −0.20 −0.22 −0.03 0.15 −0.00 0.31 −0.14
MDS-UPDRS 3 0.03 0.05 0.13 0.10 0.16 0.09 −0.02 0.10
Tremor score −0.31 0.12 −0.14 −0.09 −0.32 −0.02 −0.05 −0.21
Akinetic-rigid score 0.19 0.06 0.22 0.20 0.31 0.08 0.02 0.23
PIGD score −0.12 −0.01 0.06 −0.17 −0.20 −0.15 −0.28 −0.09
Apathy scale 0.39* 0.29 0.26 0.59** 0.45** 0.22 0.25 0.46**
PDQ-8 total 0.75** 0.64** 0.68** 0.60** 0.69** 0.47** 0.41* 0.81**
PFQ-2 total 0.62** 0.50** 0.63** 0.42* 0.53** 0.41* 0.40* 0.66**
PFQ-2 shame 0.68** 0.54** 0.73** 0.43* 0.52** 0.41* 0.26 0.69**
PFQ-2 guilt 0.40* 0.37* 0.36* 0.32 0.43* 0.34* 0.51** 0.47**
Embarrassment scale 0.63** 0.46** 0.59** 0.54** 0.68** 0.38* 0.22 0.68**
TPQ novelty seeking 0.32 0.15 0.32 0.11 0.21 −0.10 0.06 0.29
TPQ Harm avoidance 0.37* 0.44** 0.38* 0.60** 0.36* 0.20 0.24 0.46**
TPQ reward dependence 0.22 0.36* 0.28 0.14 −0.10 0.09 0.06 0.25
STAI state 0.55** 0.53** 0.43* 0.62** 0.46** 0.28 0.39* 0.62**
STAI trait 0.57** 0.64** 0.59** 0.61** 0.64** 0.48** 0.36* 0.72**
BDI-II total 0.56** 0.53** 0.43** 0.48** 0.52** 0.35* 0.47** 0.63**
Scores are expressed using Spearman rank correlation coefficient value (rS). A score rS ≥ 0.60 is considered to have a high correlation level. A score between 0.30 and 0.59 is considered
to have a moderate to high correlation level. A score < 0.30 is considered to have a moderate to weak correlation level.
*p < 0.05; **p < 0.01. p refers to the significance level of the correlation coefficients.
BDI-II, Beck Depression Inventory II; Embarr, embarrassment; LEDD, levodopa equivalent daily dose; MDS-UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating
Scale; MOCA, Montreal Cognitive Assessment; PD, Parkinson’s disease; PDQ-8, Parkinson’s Disease Questionnaire (Health-related quality of life), 8 items; PQF-2, Personal Feelings
Questionnaire (shame and embarrassment scale); TPQ, Tridimensional Personality Questionnaire; STAI, State-Trait Anxiety Inventory.
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TABLE 5 | Internal validity.
PD symptoms Physical
dependence
Body image Self Esteem Stigma Item 32
embarrassment
Physical dependence 0.59**
Body image 0.71** 0.74**
Self Esteem 0.60** 0.56** 0.49**
STIGMA 0.61** 0.47** 0.59** 0.70**
Item 32
Embarrassment
0.38* 0.58** 0.47** 0.45** 0.57**
Item 33 Shame 0.48** 0.34* 0.31 0.43** 0.53** 0.48**
Standard: rS > 0.50; * p< 0.05; ** p< 0.01.
TABLE 6 | Responses to the debriefing questionnaire about SPARK.
Answer N %
Relevance for the patient’s current
situation
No 5 14.3
Yes 30 85.7
Helpfulness for their healthcare
professionals to understand the patient’s
current situation
No 1 2.9
Yes 34 97.1
Good understandability No 0 0.0
Yes 35 100.0
Missing aspects No 24 68.6
Yes 11 31.4
Lenght No 34 97.1
Yes 1 2.9
Embarrassing questions No 32 91.4
Yes 3 8.6
Difficulty to answer questions No 31 88.6
Yes 4 11.4
Comments No 22 62.9
Yes 13 37.1
N, number of patients.
SPARK scores were related to a more pronounced personality
variant toward harm avoidance, whereas SPARK scores were
not linked with the two other personality dimensions defined
by Cloninger’s biosocial model of personality (novelty seeking
and reward dependence) (43). The harm avoidance dimension
is characterized by a tendency to respond intensely to signals
of aversive stimuli, thereby learning to inhibit behavior to
avoid punishment, novelty and frustrative non rewarding
situations. Individuals with higher levels of harm avoidance show
anticipatory worry, fear of uncertainty, shyness with strangers
as well as fatigability and asthenia. Yet harm avoidance has
been linked with hypodopaminergic behaviors such as apathy,
depression, anxiety, irritability, and hyperemotionality (44–46)
as well as with PD (47). In addition, SPARK scores were
strongly related with higher levels of depression and anxiety, and
moderately associated with the level of apathy. We hypothesized
a dopaminergic modulation to embarrassment and shame in PD.
We expect that shame and embarrassment would decrease in the
case of hyperdopaminergia (euphoria, hyperactivity, hypomania,
and impulse control disorders) when also depression, anxiety,
apathy and harm avoidance largely disappear. This assumption
remains to be elucidated.
No relationship was found between the intensity of PD-
induced shame and embarrassment and PD duration and
the severity of motor symptoms. These results might suggest
that other factors might be involved in the intensity of the
shame and embarrassment. A longitudinal study investigating
the evolution of SPARK scores depending on the phase of
PD would be interesting. Our hypothesis is that the intensity
of shame and embarrassment might be higher before the
dopaminergic replacement therapy is introduced and during the
early post-diagnosis phase when the patient is learning to adapt
to her/his disease. Another hypothesis would be that shame
and embarrassment are little related with motor symptoms as
compared with neuropsychiatric symptoms.
Nevertheless, our scale contains several limitations. Three
items presented low item-total corrected correlations with their
respective subscales. Two pairs of items showed high inter-
item correlation which might suggest redundancy. This aspect
will be checked during the validation study in a larger sample.
As pointed out by the debriefing questionnaire, some aspects
contributing to shame and embarrassment were missing. Some
new items were consequently added (stiffness, dysarthria, dry
mouth, posture difficulties) in order to capture the topic as
comprehensively as possible. The final version of SPARK will
be utilized during the future validation study. As mentioned
by several patients and because of the type of rating scale
that we chose, SPARK measures the intensity of shame and
embarrassment but not the frequency of the occurrence of these
two emotions. SPARK also does not differentiate clearly if shame
and embarrassment are internal or external. Internal shame
or embarrassment describes the negative evaluation a person
applied to her/himself whereas external shame or embarrassment
relates to the evaluation of what the person believes others
think about her/him i.e. the distressing awareness that “I think
others view me negatively” (48). The amount of psychosocial
support received by patients was not able to be measured. It is
however data that may well influence PD-induced shame and
embarrassment and in this sense, should be taken into account
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in future studies. Finally, SPARK could encounter difficulties at a
linguistic level in non-English or non-French speaking countries.
Indeed, the distinction between shame and embarrassment may
not be obvious depending on the language. In Spanish for
example, the distinction between shame and embarrassment does
not exist in the common (everyday life) language. For this reason,
we chose to combine embarrassment and shame as a single
combined score. Future studies should also address the role of
culture on shame and embarrassment in PD. How emotions
are understood and expressed varies across cultures (40, 41).
Some social groups view the self in individualistic psychological
terms as a self that is bounded, separate from others. Shame
and embarrassment are then perceived as a psychological event
occurring inside an individual. Meanwhile, other cultures favor
a collectivist conception wherein shame and embarrassment are
emotions that happen interpersonally, outside, between people
(39). The appraisal of how shame and embarrassment are felt and
expressed, as well as the responsibility for resolving them, also
varies (38). International studies are needed, with a more diverse
sample of PD patients in order to explore cultural differences
regarding the embarrassment and shame by a formal study.
Finally, our sample size was relatively small.
In conclusion, the SPARK scale could be a reliable
questionnaire which promptly measures the severity of shame
and embarrassment specifically induced in patients in the context
of PD. A validation study would be useful to confirm this
assumption. The availability of this rating scale could raise
awareness on these two emotions in PD. The SPARK scale
could help healthcare professionals to identify the problem
of shame and embarrassment affecting PD patients and to
better understand what clinically promotes these two emotions.
Our study demonstrated that PD-associated embarrassment is
extremely frequent. Shame and embarrassment were associated
with a lower level of health-related quality of life, as well
as with higher levels of depression and anxiety. As such,
PD-related shame and embarrassment deserve our attention.
Further studies are needed to deepen the understanding of
the subject, such as studies exploring clinical, cultural or
socioeconomic factors influencing these two painful emotions.
The clinical implication of this score system could be
important especially in patients who score high on SPARK total
score and shame sub-item as shame probably contributes to
psychological difficulties such as personal distress, depression,
suicidal ideation, and social encounter avoidance. A high
SPARK score should alert healthcare professionals to the
potential presence of psychological difficulties. The SPARK
questionnaire could therefore help healthcare professionals
to implement psychological support to patients’ management
in a timely fashion in order to help patients cope with
their disease. Cognitive-behavioral intervention strategies such
as systematic desensitization, role playing, thought stopping,
disputing the inner critic, identification of irrational thinking
and dysfunctional cognitive schemas could be clinically beneficial
for these 2 emotions (49, 50). The SPARK scale could also
help indirectly researchers to better understand the biological
role of monoaminergic neurotransmitter depletion in these
negative emotions. Understanding the biology behind shame
and embarrassment could allow more targeted pharmacological
management in addition to enhancing coping strategies.
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